Literature DB >> 28240749

Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Phyu P Aung1, Priyadharsini Nagarajan1, Victor G Prieto1.   

Abstract

Though not required currently for staging, regression is a histopathologic parameter typically reported upon diagnosis of an invasive primary cutaneous melanoma. The studies examining the prognostic significance of regression in patient outcome have yielded controversial findings; likely because the definition and assessment of regression have not been consistent, in addition to subjectivity of pathologists' interpretation. Regression is histologically characterized by variable decrease in the number of melanoma cells accompanied by the presence of a host response consisting of dermal fibrosis, inflammatory infiltrate, melanophages, ectatic blood vessels, epidermal attenuation, and/or apoptosis of keratinocytes or melanocytes; the relative extent of these features depends on the stage of the regression. However, the magnitudes to which these individual changes must be present to meet the threshold of histologic regression have not been well defined or agreed upon, and thus, the definition and classification of histologic regression in melanoma varies considerably among institutions and even among individual pathologists. In order to determine the clinical significance of histologic analysis of regression, there is a compelling need for a universal scheme to objectively define and assess histologic regression in primary cutaneous melanoma, so that the biologic and prognostic significance of this process may be completely understood.Laboratory Investigation advance online publication, 27 February 2017; doi:10.1038/labinvest.2017.8.

Entities:  

Year:  2017        PMID: 28240749     DOI: 10.1038/labinvest.2017.8

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  107 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

3.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

Review 4.  Metastatic malignant melanoma with spontaneous and complete regression of the primary lesion. Case report and review of the literature.

Authors:  A Shai; I Avinoach; A Sagi
Journal:  J Dermatol Surg Oncol       Date:  1994-05

5.  Biologic behavior of thin malignant melanomas with regressive changes.

Authors:  R R Paladugu; R H Yonemoto
Journal:  Arch Surg       Date:  1983-01

6.  Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).

Authors:  Alessandro Testori; Gian Luca De Salvo; Maria Cristina Montesco; Giuseppe Trifirò; Simone Mocellin; Giorgio Landi; Giuseppe Macripò; Paolo Carcoforo; Giuseppe Ricotti; Giuseppe Giudice; Franco Picciotto; Davide Donner; Franco Di Filippo; Javier Soteldo; Dario Casara; Mauro Schiavon; Antonella Vecchiato; Sandro Pasquali; Federica Baldini; Giovanni Mazzarol; Carlo Riccardo Rossi
Journal:  Ann Surg Oncol       Date:  2009-01-09       Impact factor: 5.344

7.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

8.  Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.

Authors:  P H Cooper; H J Wanebo; R W Hagar
Journal:  Arch Dermatol       Date:  1985-09

9.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

10.  Adaptive immune cells temper initial innate responses.

Authors:  Kwang Dong Kim; Jie Zhao; Sogyong Auh; Xuanming Yang; Peishuang Du; Hong Tang; Yang-Xin Fu
Journal:  Nat Med       Date:  2007-09-23       Impact factor: 53.440

View more
  15 in total

1.  The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution.

Authors:  Ajit J Nirmal; Zoltan Maliga; Tuulia Vallius; Sandro Santagata; Peter K Sorger; Brian Quattrochi; Alyce A Chen; Connor A Jacobson; Roxanne J Pelletier; Clarence Yapp; Raquel Arias-Camison; Yu-An Chen; Christine G Lian; George F Murphy
Journal:  Cancer Discov       Date:  2022-06-02       Impact factor: 38.272

2.  Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?

Authors:  Laura A Taylor; Megan M Eguchi; Lisa M Reisch; Andrea C Radick; Hannah Shucard; Kathleen F Kerr; Michael W Piepkorn; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Joann G Elmore
Journal:  Cancer       Date:  2021-05-04       Impact factor: 6.860

Review 3.  Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.

Authors:  Helena Kupcova Skalnikova; Jana Cizkova; Jakub Cervenka; Petr Vodicka
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

4.  Clinicopathologically problematic melanocytic tumors: a case-based review.

Authors:  Zoe Apalla; Christina Nikolaidou; Aimilios Lallas; Elena Sotiriou; Elizabeth Lazaridou; Ioannis Venizelos; Mattheos Bobos; Efstratios Vakirlis; Demetrios Ioannides; Gerardo Ferrara
Journal:  Dermatol Pract Concept       Date:  2018-10-31

5.  A diagnostic autoantibody signature for primary cutaneous melanoma.

Authors:  Pauline Zaenker; Johnny Lo; Robert Pearce; Phillip Cantwell; Lester Cowell; Mark Lee; Christopher Quirk; Henry Law; Elin Gray; Mel Ziman
Journal:  Oncotarget       Date:  2018-07-17

6.  Comparative analysis of CEACAM1 expression in thin melanomas with and without regression.

Authors:  Luciana Nichita; Sabina Zurac; Alexandra Bastian; Patricia Stinga; Roxana Nedelcu; Alice Brinzea; Gabriela Turcu; Daniela Ion; Lucia Jilaveanu; Liana Sticlaru; Cristiana Popp; Mirela Cioplea
Journal:  Oncol Lett       Date:  2019-02-25       Impact factor: 2.967

Review 7.  FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation.

Authors:  Mirela Cioplea; Luciana Nichita; Daniela Georgescu; Liana Sticlaru; Alexandra Cioroianu; Roxana Nedelcu; Gabriela Turcu; Alin Rauta; Cristian Mogodici; Sabina Zurac; Cristiana Popp
Journal:  J Immunol Res       Date:  2020-10-23       Impact factor: 4.818

8.  Protocol for the Histologic Diagnosis of Cutaneous Melanoma: Consensus Statement of the Spanish Society of Pathology and the Spanish Academy of Dermatology and Venereology (AEDV) for the National Cutaneous Melanoma Registry.

Authors:  A Tejera-Vaquerizo; M T Fernández-Figueras; A Santos-Briz; J J Ríos-Martín; C Monteagudo; A Fernández-Flores; C Requena; V Traves; M A Descalzo-Gallego; J L Rodríguez-Peralto
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2020-10-07

9.  Atypical Cardiac Location of Melanoma of Unknown Origin.

Authors:  Agnieszka Styczeń; Mariusz Kozak; Marta Karaś-Głodek; Elżbieta Czekajska-Chehab; Andrzej Tomaszewski; Andrzej Wysokiński; Tomasz Zapolski
Journal:  Medicina (Kaunas)       Date:  2021-01-25       Impact factor: 2.430

10.  Early melanoma invasivity correlates with gut fungal and bacterial profiles.

Authors:  F Vitali; R Colucci; M Di Paola; M Pindo; C De Filippo; S Moretti; D Cavalieri
Journal:  Br J Dermatol       Date:  2021-10-10       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.